Zealand Pharma fined by Danish financial supervisory authority

The Danish FSA claims the biotech firm hasn’t released information concerning a major stakeholder’s shareholding, which will cost the firm DKK 60,000 (USD 8,246) in penalties.

Photo: Andrew Kelly/REUTERS / X02844

Danish biotech firm Zealand Pharma has been fined DKK 60,000 (USD 8,246) by Denmark’s Financial Supervisory Authority, the FSA, according to a press release from the agency.

The FSA says Zealand Pharma has neglected to publish information pertaining to changes in a major shareholder’s holding of shares in the firm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs